Close Menu

NEW YORK – Vermillion reported after the close of the market on Thursday a 55 percent year-over-year rise in first quarter revenues.

For the three months ended March 31, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $1.2 million from $779,000 in the year-ago quarter.

Revenues for the recently completed quarter were derived from 3,654 OVA1 tests performed, up 58 percent from the 2,313 OVA1 tests performed in Q1 2019. Revenue per test was $324, down 4 percent from $337 in Q1 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.